Hepatitis C future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
Line 8: Line 8:
Several investigational drugs are being tested for use in hepatitis C. These agents focus on proteins essential for viral replication. The table below summarizes the agents currently being investigated.
Several investigational drugs are being tested for use in hepatitis C. These agents focus on proteins essential for viral replication. The table below summarizes the agents currently being investigated.


{| {{table}}
{| {{table|center|700px}}
| align="center" style="background:#f0f0f0;"|'''Name'''
| align="center" style="background:#f0f0f0;"|'''Name'''
| align="center" style="background:#f0f0f0;"|'''Alternative'''
| align="center" style="background:#f0f0f0;"|'''Alternative'''

Revision as of 19:50, 29 July 2014

Hepatitis Main Page

Hepatitis C

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology & Demographics

Risk Factors

Screening

Differentiating Hepatitis C from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Hepatitis C future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis C future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis C future or investigational therapies

CDC on Hepatitis C future or investigational therapies

Hepatitis C future or investigational therapies in the news

Blogs on Hepatitis C future or investigational therapies

Directions to Hospitals Treating Hepatitis C

Risk calculators and risk factors for Hepatitis C future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor-In-Chief: Nina Axiotakis [2]

Overview

Future Or Investigational Therapies

Several investigational drugs are being tested for use in hepatitis C. These agents focus on proteins essential for viral replication. The table below summarizes the agents currently being investigated.

Name Alternative Mechanism of Action
Danoprevir[1] RG7227/ITMN-191 Inhibitor of the HCV NS3/4A serine protease
Asunaprevir[2] BMS-650032 Inhibitor of the HCV NS3/4A serine protease
Vaniprevir[3] MK-7009 Inhibitor of the HCV NS3/4A serine protease
Daclatasvir[4] BMS-790052 Inhibitor of the HCV non-structural protein NS5A
Mericitabine[5] RG7128 Inhibitor of the HCV NS5B polymerase
Ledipasvir[6] GS-5885 Inhibitor of the HCV non-structural protein NS5A
Faldaprevir[7] BI-2010335 Protease inhibitor

References

  1. Jiang Y, Andrews SW, Condroski KR, Buckman B, Serebryany V, Wenglowsky S; et al. (2014). "Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease". J Med Chem. 57 (5): 1753–69. doi:10.1021/jm400164c. PMID 23672640.
  2. Eley T, He B, Chang I, Colston E, Child M, Bedford W; et al. (2014). "The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor". Antivir Ther. doi:10.3851/IMP2773. PMID 24704773.
  3. Lawitz E, Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Bhanja S; et al. (2013). "A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment". J Hepatol. 59 (1): 11–7. doi:10.1016/j.jhep.2013.02.008. PMID 23439259.
  4. Herbst DA, Reddy KR (2013). "NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection". Expert Opin Investig Drugs. 22 (10): 1337–46. doi:10.1517/13543784.2013.826189. PMID 23931586.
  5. Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C; et al. (2013). "JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients". Hepatology. 58 (2): 514–23. doi:10.1002/hep.26275. PMID 23359491.
  6. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E; et al. (2014). "Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis". N Engl J Med. 370 (20): 1879–88. doi:10.1056/NEJMoa1402355. PMID 24720702.
  7. Nishiguchi S, Sakai Y, Kuboki M, Tsunematsu S, Urano Y, Sakamoto W; et al. (2014). "Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection". Liver Int. 34 (1): 78–88. doi:10.1111/liv.12254. PMID 23944720.

Template:WH Template:WS